Lantheus Medical Imaging, Inc., a worldwide leader in diagnostic imaging, today announced that data from the Phase 2 clinical trial for the assessment of myocardial perfusion using Positron Emission Tomography (PET) imaging of flurpiridaz F 18 in patients with suspected or known coronary artery disease (CAD) will be presented in a series of oral and poster presentations at the SNM 58th Annual Meeting, being held June 4-8 in San Antonio. In addition, the Company will be presenting data on LMI 1195, a novel cardiac neuronal PET imaging agent in development to improve the evaluation and management of patients with heart failure.
